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Protoporphyrin IX (PpIX) synthesis by malignant cells is clinically exploited for photodiagnosis and photodynamic therapy following
administration of 5-aminolevulinic acid (ALA). The expression and activity of the housekeeping porphobilinogen deaminase (PBGD)
was correlated to PpIX synthesis in differentiating B16 melanoma cells. Differentiation was stimulated by two inducers, butyrate and
hexamethylene bisacetamide (HMBA), both of which promote the formation of typical melanosomes and melanin, as well as
morphological changeover. A marked decrease in total PBGD activity and PpIX synthesis was observed following stimulation by
butyrate, while HMBA induced an opposite effect. In contrast, ferrochelatase levels remained unchanged. Photodynamic inactivation
of the cells undergoing differentiation was largely dependent on the PpIX accumulation, which was modulated by the two inducers
butyrate and HMBA. Fluorescence immunostaining with anti-PBGD antibodies revealed a major PBGD fraction in the nucleus and a
minor fraction in the cytosol. This nuclear localisation pattern was confirmed by expression of PBGD fused to green fluorescence
protein. We suggest that efficient photodynamic therapy of cancer facilitated by ALA administration can be enhanced using combined
therapeutic modalities.
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Photodynamic therapy (PDT) is used to treat both cancer and non-
cancerous conditions. This treatment utilises a combination of
photosensitising chemicals and visible light, usually light in the red
or near infrared region, which is compatible with the absorption
spectrum of the specific drug. (Dougherty et al, 1998).
Cancer cells in vitro and in solid tumours have been reported to
exhibit an enhanced capacity for protoporphyrin IX (PpIX)
synthesis facilitated by the administration of the pro-drug 5-
aminolevulinic acid (ALA) (Zeitouni et al, 2003). This enhanced
capacity is exploited clinically for PDT and photo-diagnosis (Peng
et al, 1997). Aminolevulinic acid is the first intermediate molecule
in the heme biosynthesis pathway and is formed when ALA
synthase condenses glycine and succinyl CoA in the mitochondria.
Two ALA molecules combine in the cytosol to form porphobilino-
gen (PBG). Porphobilinogen deaminase (PBGD) then combines
four molecules of PBG into hydroxymethylbilane, which is turned
into uroporphyrinogen III. Uroporphyrinogen III converts to
coproporphyrinogen and then, after reuptake in mitochondria, to
PpIX (Szeimies et al, 1996; Ponka, 1997; Gibson et al, 1998).
Fluorescence microscopy data suggest that because of the localisa-
tion of PpIX in the mitochondria, the primary cause of cell death
after PDT is mitochondrial phototoxicity (Iinuma et al, 1994).
Aminolevulinic acid is considered to be one of the most
promising agents among the approved PDT sensitisers for a variety
of malignant tumours, especially for skin cancers (Henderson et al,
1995; Abels et al, 1997). Malignant melanoma is the most life-
threatening skin cancer and accounts for approximately three-
quarters of all skin cancer deaths, since traditional forms of
chemotherapy have little effect on this tumour (Rusciano, 2000;
Bastuji-Garin and Diepgen, 2002). Aminolevulinic acid treatment
of B16 melanoma cells induces PpIX biosynthesis and facilitates
the photodynamic killing of these cells (Schoenfeld et al, 1994; De
Rosa and Bentley, 2000; Juzenas et al, 2002). Several mechanisms
have been suggested as being involved in the photodynamic
process, including a lower intracellular iron concentration,
lowered ferrochelatase activity, higher permeability of ALA into
tumours, higher local temperature and higher PBGD activity in
malignant cells (el-Sharabasy et al, 1992; Ackermann et al, 1998;
Gibson et al, 1998).
Porphobilinogen deaminase is one of the rate-limiting enzymes
in heme biosynthesis and it is expressed as two isoforms, a
‘houskeeping’ isoform present in all cell types and a second
isoform expressed only in erythroid cells (Raich et al, 1986;
Grandchamp et al, 1987; Sassa, 1990). We have recently shown that
a major fraction of PBGD in C6 glioma cells is localised in the
nucleus, in addition to the cytosolic fraction active in PpIX
synthesis (Greenbaum et al, 2002). Furthermore, overexpression of
the human housekeeping PBGD has been found to induce C6
differentiation toward astrocytes.
In this study, B16 melanoma cells were treated with two known
differentiation agents, sodium butyrate and HMBA. Butyrate has
been shown to accumulate during the G1 phase, influence gene
expression and induce terminal differentiation (Toscani et al, 1988;
Demary et al, 2001) even in melanoma cells (Nordenberg et al,
1987). It has been suggested that butyrate acts as a histone
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sdeacetylase inhibitor and thus the fraction of acetylated histones is
dominant and the corresponding genes are transcribed. HMBA is a
prototype of the hybrid polar differentiation inducer of many cell
types, especially erythroleukaemia (Marks et al, 1987; Marks et al,
1994). HMBA induces the porphyrin biosynthesis pathway
expression of globin genes and differentiation (Marks et al,
1987). Ortel et al (1998) have demonstrated that cellular
differentiation increases the ability of a variety of cells to
synthesise PpIX from exogenous ALA.
The purpose of this study was to correlate between ALA-PDT
efficacy with modulation of PBGD expression and activity by
chemically induced differentiation in B16 melanoma cells, and
consequently to advance the understanding of the molecular basis
of ALA-PDT specificity in clinical applications.
MATERIALS AND METHODS
Cell cultures
A B16 F10 mouse melanoma cell line was purchased from
American Type Culture Collection. The cells were grown in RPMI
1640 (B16 F10) medium (Biological Industries, Beit-Haemek,
Israel) supplemented with 10% foetal calf serum and antibiotics
at 371C in a humidified atmosphere with 5% CO2 and 95% air. The
cells were passaged twice weekly.
Cell differentiation induction
Hexamethylene bisacetamide (HMBA, 5mM) or 2.5mM sodium
butyrate (Butyrate) (Sigma Chemical Co, St Louis, MO, USA) were
added to the cells in complete medium. The cells were washed with
PBS after 24, 48 or 72h and harvested by centrifugation.
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide (MTT) assay
The effect on cell proliferation was measured using a modified
MTT assay based on the ability of live cells to cleave the
tetrazolium ring to a molecule that absorbs at 590nm in active
mitochondria (Mosmann, 1983). 2 10
3 cells were grown in 96-
well plates. The treatment medium was replaced and 20ml MTT
reagent (5mg/1ml PBS) (Sigma, Chemical Co, St Louis, MO, USA)
was added to each well. The cells were further incubated at 371C
for 2h. For lysis of the cells, N,N-dimethyl formamide was added to
the media for 5h and absorbance was then measured at 570nm.
Scanning electron microscopy
The cells were fixed with 2.5% glutaraldehyde in phosphate buffer
(pH 7.2), washed in the same buffer and post fixed with 2% OsO4.
The third step of fixation was performed using a solution of tannic
acid and guanidine hydrochloride. The triple-fixed cells were
dehydrated in graded alcohol solutions. The alcohol was then
exchanged for Freon-112 using graded Freon solutions. The cells
were air-dried, gold coated and examined using a Jeol 840
scanning electron microscope.
Transmission electron microscopy
The cells were fixed in 2.5% gluteraldehyde/2% formaldehyde in
phosphate buffer solution (pH 7.4). The cells were removed with a
Costarcell scraper, postfixed in 1% OsO4, dehydrated and
embedded in Epon 812. Thin sections were prepared using an
LKB Ultratome III and stained with uranyl acetate followed by lead
citrate. The sections were examined using a JEOL 1200ex
transmission electron microscope.
Aminolevulinic acid treatment and photosensitisation
B16 melanoma cells were seeded into dishes and treated with
butyrate and HMBA as described above. After 48h, the medium
was replaced in the dark by serum-free medium, with or without
0.1mgml
 1 ALA (Clontech, Palo Alto, CA, USA) for 4h. At the end
of the incubation period, the cells were irradiated using a Vilber
Lourmat lamp, VL-206BL, delivering a power density of
22.5mWcm
 2 at 360–410nm (max. at 365nm). Light intensity
was measured with a Nova photometer (Ophir Optronics,
Jerusalem).
Annexin reaction
2 10
3 cells were grown in 24-well plates, the cells were treated
with ALA, butyrate and HMBA as described above and then
irradiated for different light doses. After an additional 24h,
Annexin V-fluorescein isothiocyanate (FITC), propidium iodide
(PI) and bisBENZIMIDE (Hoechst No 33258) were added to the
cells according to the manufacturer’s protocol (Sigma, Chemical
Co, St Louis, MO, USA). Annexin allows fluorescent detection of
Annexin V bound to apoptotic cells. The Annexin V is conjugated
with FITC to label phosphatidylserine sites on the membrane
surface. Propidium iodide was added to the cells in order to label
the cellular DNA in necrotic cells where the cell membrane has
been totally compromised. Hoechst was added in order to label the
nucleus; a blue colour marked live cells, while a pink colour
marked necrotic cells (Kuypers et al, 1996).
DNA electrophoresis
Cells were treated with ALA, butyrate and HMBA as described
above and then irradiated for different light doses. After an
additional 24h, the DNA was isolated and electrophoresed (Lund
et al, 2002).
Flow cytometry of cellular PpIX
B16 melanoma cells were grown on tissue culture plates and were
incubated with or without 2.5mM butyrate or 5mM HMBA for 48h.
Aminolevulinic acid (Fluka, Sigma Diagnostics, St Louis, MO,
USA) was diluted in RPMI-1640 medium to a stock solution of
10mgml
 1 and a final concentration of 0.1mgml
 1 was incubated
with cells for 4h. After incubation with ALA, the cells were washed
with PBS (without Ca
þ2 and Mg
þ2) and scraped off with a rubber
policeman. After 10min of centrifugation at 1100r.p.m., the
medium was decanted and 0.5ml of PBS (without Ca
þ2 and
Mg
þ2) was added. The suspension was filtered and measured
using a Fluorescence-Activated Cell Sorter (Becton Dickinson
FACS Calibur, Mountain View, CA, USA). In all, 10000 cells were
measured in each sample (ex. 488nm, em. LP 670nm).
PpIX accumulation assay
B16 melanoma cells were treated with butyrate and HMBA for
certain periods of time. At 4h before each point of time,
0.1mgml
 1 5-ALA (Clontech, Palo Alto, CA, USA) in serum-free
medium was added to the cells. At the end of the incubation
period, the cells were detached from the plates and centrifuged at
1100r.p.m., followed by resuspension in glacial acetic acid. The
cells were sonicated on ice and ethyl acetate was added (vv
 1 1:3).
The samples were centrifuged at 3300r.p.m. for 15min, and the
supernatant was transferred to 1 M HCl. After 5min of shaking, the
lower phase was collected and read using a spectrofluorometer (ex.
405, em. 620). The results were calculated as the mean of five
experiments and expressed as %PpIX formed per mg protein
during 4h of incubation with 5-ALA.
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sWestern blotting
Proteins were quantified using the Bradford assay (Bio-Rad,
Hercules, CA, USA) and resolved in a 12% polyacrylamide gel. The
proteins were then transferred onto a nitrocellulose membrane
using a semi-dry transfer apparatus (Bio-Rad, Hercules, CA, USA).
After blocking of the membrane with 5% skim milk and 0.06%
Tween-20 in PBS, the membrane was incubated with primary
PBGD antibody (a generous gift from HemeBiotech, Sweden)
primary ferrochelatase antibody (EnVirtue Biotechnologies,
Walnut Creek, CA, USA), primary actin antibody (Sigma,
Chemical Co, St Louis, MO, USA) or primary RCC1 antibody
(Santa Cruz Biotechnology, California, USA) and goat anti-rabbit,
goat anti-mouse and donkey anti-goat secondary antibodies
(Jackson Immuno-Research, West Grove, PA, USA) in the
same solution. Immunoreactive proteins were visualised with
an enhanced chemiluminescence detection kit (Pierce Bio-
technology, Rockford, IL, USA) used as recommended by the
manufacturer.
Porphobilinogen deaminase enzymatic activity assay
Porphobilinogen deaminase was assayed by determination of the
absorbance of uropophyrin formed by light-induced oxidation of
uroporphyrinogen, the immediate product of the enzymatic
deamination. In all, 10
6 B16 melanoma cells were detached from
plates after incubation with the differentiation inducers and
resuspended in PBS without Ca
2þ/Mg
2þ. After centrifugation,
the pellet was resuspended in 1ml 50mM Tris (pH 8.2). In all,
250ml of the lysate was incubated with an equivalent amount of
50mM Tris buffer, pH 8.2, containing 2% Triton X-100 and 100ml
0.5mM PBG (Porphyrin Products, Logan, UT, USA) for 1h with
shaking at 371C. The reaction was stopped with the addition of
10% TCA under exposure to ambient room light at room
temperature for 10min. After 10min centrifugation (3300r.p.m.),
the supernatant was transferred to the spectrofluorometer (ex.
409nm, em. 595nm) (Spectronic Instruments, Leeds, UK).
Porphobilinogen deaminase specific activity is expressed as pmol
uroporphyrin formed(mg protein)
 1h
 1.
Nucleus-cytoplasm fractionation
B16 melanoma cells were harvested and resuspended in Tris-HCl
buffer supplemented with EDTA, EGTA and the antiproteases
leupeptin, aprotinine, PMSF and DTT (Sigma, St Louis, USA). For
nucleus cytoplasm fractionation, the cells were homogenised on
ice, followed by centrifugation at 2500r.p.m. for 10min (twice),
and the nuclear fraction was resuspended in the above buffer. For
Western blotting of each fraction, Triton X-100 was added and the
sample was immersed in liquid nitrogen and thawed at 371C
intermittently, followed by centrifugation at 14000r.p.m. for
20min. RCC1 levels were used as a nuclear fraction indicator
(Figure 7).
Porphobilinogen deaminase immunolabelling
Cells were seeded in eight-well chamber slides. After 24h, the cells
were fixed using 4% paraformaldehyde and were subsequently
treated with 0.5% Triton X-100 for 30min. Blocking was carried
out with 6% skim milk, 3% BSA and 0.2% Tween 20 in 100% FCS.
The cells were then exposed to the primary antibody, anti-PBGD,
overnight at 41C. Reacting rhodamine-conjugated donkey anti-
rabbit (Jackson Immuno-Research, West Grove, PA, USA), ex.
570nm, was visualised with fluorescence microscopy (Olympus
AX70). As a control, anti-PBGD antibody was withdrawn from the
samples and the cells were exposed only to the second antibody,
rhodamine-conjugated donkey anti-rabbit.
Preparation of fragments of PBGD fused to GFP
All the coding regions of the fragments were amplified from pHK-
PBGD (pLY-81) (Greenbaum et al, 2002) using different primers
for each fragment. The PCR products were cut by the restriction
enzymes BglII and EcoRI, and were ligated to pEGFP-N1 (Clontech,
Palo Alto, CA, USA) in frame. Constructs were verified by
sequencing (Weitzmann Institute Biological Services, Rehovot,
Israel).
Transfection of plasmids to the cells
B16 melanoma cells were incubated in serum-free medium for
40min, followed by 5h incubation in a transfection solution
containing 1.33mgml
 1 of each plasmid and 10ml lipofectamine
reagent (Life Technologies, (GIBCO-BRL), Gaithersburg, MD,
USA) in RPMI. Following transfection, the cells were transferred
to a rich medium containing serum and antibiotic. GFP (ex.
395nm) was visualised with fluorescence microscopy (Olympus
AX70).
RESULTS
Mitochondrial and cytosolic enzymes carry out heme synthesis,
where PBGD, the third enzyme in the pathway, plays a major
regulatory role. It has been suggested that the proliferation rate
and cellular differentiation are major determinates in the
regulation of heme pathway (Boldt, 1999). In order to characterise
the interrelationship between PDT efficacy to porphyrin synthesis,
PBGD expression and differentiation, we induced differentiation in
B16 melanoma cells using two chemical inducers butyrate and
HMBA. The attenuation in cell proliferation following butyrate and
HMBA induction was assayed using the MTT reaction (Figure 1A).
The time-dependent reduction in cell viability by treatment with
2.5mM butyrate or 5mM HMBA after 24–72h (Figure 1A), was
accompanied by accumulation of 60% of the cells in the G1 phase,
whereas for the cells that were not treated with a differentiation
inducer 37% of the cells were in G1 (data not shown).
Melanin synthesis and formation of dendritic projections are
considered as characteristic differentiation markers of B16 cells
(Nordenberg et al, 1987), both of which were demonstrated by
induction with butyrate and HMBA (Figure 1). The s.e.m.
micrographs of cells after 48h of butyrate and HMBA induction
reveal a morphological changeover from round-shaped control
cells to star-like flattened cells (Figure 1B). Transmission electron
microscopy showed melanin synthesis, with formation and fusion
of melanosomes following induction by both butyrate and HMBA
in comparison to control cells (Figure 1C).
Photodynamic therapy efficacy when using butyrate or HMBA-
induced cells treated with ALA showed a tight dependency between
viable cells and specific differentiation route. The percentage of
viable cells at 24h post photoirradiation was lowest in HMBA-
treated cells in comparison to ALA and butyrate-treated cells
(Figure 2A) measured by the MTT assay. The Annexin reaction of
the photodynamic inactivated cells showed positive staining for
most of the cells treated by HMBAþALA, while this was true for
only 30% of the butyrateþALA-treated cells. The photo-inacti-
vated HMBAþALA cells revealed nuclear staining by PI, which is
a strong indication of auto-membrane perforation due to PDT
(Figure 2B). Cell death following photosensitisation was char-
acterised by a typical DNA fragmentation pattern and necrotic and
apoptotic features revealed with electron microscopy (Figure 3A).
Agarose DNA electrophoresis showed DNA laddering after ALA-
PDT of the B16 cells and after HMBA-induced differentiation and
ALA-PDT. No DNA laddering was revealed after butyrate-induced
differentiation and ALA-PDT. Side by side, apoptotic and necrotic
features such as the typical membrane blebbing and membrane
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electron microscopy (Figure 3B).
Hasan and co-workers have shown that induction of prostate
cancer cell differentiation augments intracellular PpIX accumula-
tion (Ortel et al, 1998). Similarly, DMSO induced differentiation of
B16 cells enhanced by PpIX accumulation (Schoenfeld et al, 1994).
Figure 4 shows that PpIX synthesis in the B16 cells is dependent on
the differentiation agents, butyrate or HMBA, in two distinct and
opposite modes. PpIX flow cytometry and PpIX extraction, both
showed that butyrate induction plus ALA supplementation for 4h
promoted a low capacity of PpIX synthesis, in comparison to cells
treated only with ALA. Alternatively, HMBA plus ALA induced a
marked increase in PpIX synthesis and accumulation in the B16
cells (Figure 4).
It has been suggested that during differentiation and reduction
in heme synthesis, the activity of the third enzyme in the
porphyrin synthesis pathway, PBGD, would be altered accordingly
(Ortel et al, 1998). Porphobilinogen deaminase during butyrate-
induced differentiation of B16 cells was analysed by Western
blotting, revealing a time-dependent decrease in total PBGD
protein (Figure 5A). The specific enzymatic activity of PBGD was
reduced (Figure 5B) as a time-dependent effect following butyrate
treatment. In contrast, the effect of the second inducer, HMBA, was
the opposite, revealing a time-dependent increase in total PBGD
(Figure 5A), as well as an increase in the specific enzymatic activity
(Figure 5B). Actin levels were used as an internal protein control.
We have already shown that the major fraction of PBGD in C6
glioma cells was found in the nucleus (Greenbaum et al, 2002).
Figure 6 reveals the subcellular localisation of PBGD in B16
melanoma cells. The fluorescence immunolabelling with specific
anti-human PBGD antibodies shows that a large fraction of
PBGD was localised in the nucleus of the B16 melanoma cells
(Figure 6A). This result was affirmed by transfection of the B16
cells by the plasmids pLY1 and pLY2, encoding PBGD fused to GFP
at either the C terminal or N terminal, respectively. Expression of
pLY1 and pLY2 in the B16 cells showed clearly a major fraction of
newly synthesised fused GFP-PBGD in the nucleus (Figure 6B–C),
while control cells transfected with wild-type GFP (pE-GFP-C1)
showed diffused fluorescence throughout the cytoplasm
(Figure 6D).
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Figure 1 Effect of butyrate and HMBA on the morphology and cell proliferation of B16 melanoma cells. The cells were incubated with 2.5mM butyrate or
5m M HMBA for different times. (A) Presents the proliferation rate of the cells as detected by the MTT assay. Each point is the mean 7 SE of two to three
separate experiments. P value o0.005. (B) Scanning electron microscopy and (C) Transmission electron microscopy. The arrows indicate the presence of
melanin.
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sWestern blotting and specific enzymatic activity of the nuclear
fraction of PBGD during induced differentiation revealed a time-
dependent decrease in butyrate-treated cells. On the other hand,
HMBA-treated cells showed an opposite effect: nuclear PBGD
protein levels and activity were increased in a time-dependent
manner (Figure 7A–B). Ferrochelatase, another key enzyme in
heme biosynthesis, was analysed by Western blotting and showed
an unchanged enzyme content during B16 differentiation induced
by HMBA or butyrate (Figure 8).
DISCUSSION
Rapidly proliferating cells manifest an accelerated capacity for
PpIX synthesis following ALA treatment. This property is widely
used for PDT and photodiagnosis of solid tumours. The relation-
ship between heme biosynthesis and proliferation, differentiation
and apoptosis is not well understood. It is conceivable that PBGD
is a rate-limiting enzyme and a regulatory checkpoint in porphyrin
biosynthesis. It has been proposed that changes in the PBGD
activity are closely related to growth (Boldt, 1999). Furthermore,
PBGD and ALA dehydrase (ALAD) activities seem to be greater in
some malignant tissues than in normal tissue (Mamet et al, 1994).
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Figure 2 The effect of ALA and photo-irradiation on differentiated B16
melanoma cells. (A) The percentage of viable cells 24h post photoirradia-
tion was measured by an MTT assay. (B) Annexin reaction of irradiated
cells with 3.75Jcm
 2. The original photomicrographs mirror the intrinsic
colors of the reactive materials I and II. Control cells were not treated with
ALA. Arrows point to necrotic cells. Figs III and IV – cells were treated with
butyrate þALA. In III arrows point to necrotic cells, and in IV – the arrows
point to apoptotic cells. Figs V and VI – cells were treated with
HMBAþALA. In V all the cells are necrotic.
Figure 3 Effect of PDT on B16 melanoma cell death after different light
doses (A) Electrophoretic ladder patterns: C-control cells, M-a marker for
multiples of 200bp fragments. (B) Scanning electron microscopy of cells
following 5-ALA-PDT.
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sOur results revealed that total PBGD was dramatically affected
during differentiation of B16 melanoma cells. Stimulation with
butyrate induced melanocytic differentiation accompanied by a
reduction in cellular PBGD as determined by Western blot
analysis, while HMBA induced similar differentiation markers
with a prominent increase in total PBGD. Similarly, the enzymatic
activity of PBGD was well correlated with total PBGD content
following butyrate and HMBA treatment. No changes were found
in total ferrochelatase during butyrate and HMBA stimulation in
Western blot analysis. It has been previously shown that malignant
tissues contain low levels of ferrochelatase, which explains the high
accumulation of PpIX following ALA treatment (Ponka, 1997).
Thus, PBGD seems to be the main checkpoint in PpIX synthesis in
our B16 melanoma system.
Our present independent methods of immunolabelling and GFP-
tagging reveal dual localisations of PBGD in B16 melanoma cells,
one cytosolic and the other nuclear. Recently, we have shown
interaction between PBGD and a nuclear protein Ran-binding
protein (Greenbaum et al, 2003). These findings are indicative of a
possible dual function of PBGD, one enzymatic in the cytoplasmic
heme pathway and an unknown role in the nucleus. Tagging the
GFP to either the N or C terminal of PBGD exhibited the same
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Figure 4 PpIX accumulation in B16 melanoma cells induced by butyrate
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Figure 5 Effect of butyrate and HMBA on total enzymatic activity of
PBGD in B16 melanoma cells. (A) Western blot analysis followed by
chemiluminescence detection of cells that were treated with 2.5mM
butyrate or 5mM HMBA for different times. The data presented here
are from a representative experiment repeated three times with similar
results. (B) Time response curve of the effect of 2.5mM butyrate and 5mM
HMBA on PBGD activity. Each point is the mean7s.e. of two to three
separate experiments, which were performed in triplicate. *Po0.05,
**Po0.005.
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snuclear localisation pattern, although the specific localising
sequence is not yet defined.
Recently, we have demonstrated that during mitosis chromatids
were intensely stained for PBGD in comparison to the interphase
chromatin (Greenbaum et al, 2003 b). Using the yeast two-hybrid
system, the RanBPM, the nuclear Ran-binding protein, was shown
to interact with PBGD. The molecular function of PBGD-Ran BPM
in the nucleus is now being explored, having in mind the finding
that PBGD is bound to chromosomes. Similarly, RanBPM was both
localised in the nucleus and cytosol, and especially surrounding
the centrosome (Nishitani et al, 2001). We speculate that the
unknown nuclear role of the PBGD in addition to its cytosolic
enzymatic activity required for heme synthesis is probably
interrelated to cell transformation and differentiation.
The prominent PBGD activity in tumours, which is responsible
for the enhanced porphyrin synthesis following ALA treatment, is
exploited clinically. Malignant glioma (Schoenfeld et al, 1988), oral
cavity cancer, colonic and gastrointestinal dysplasia (Stummer
et al, 1998a), peritoneal endometriosis (Stepp et al, 1998), lower
urinary tract tumours (Hillemanns et al, 2000), bladder cancer
(Kriegmair et al, 1999), malignant mucosa in head and neck cancer
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D
Figure 6 Nuclear localisation of PBGD in B16 melanoma cells (A)I n
immuno-labelling, the nuclear versus cytoplasmic distribution of PBGD was
similar for all experiments. In control cells, in which anti-PBGD antibody
was withdrawn from the samples, there was no signal. Original
magnification X 60, bar 5mm. (B,C) Over expression of human
housekeeping PBGD fused to GFP on the N-terminal (B) or the C-
terminal (C). (D) The negative control for nuclear GFP localisation was cells
expressing the wild type GFP plasmid and revealing diffused fluorescence.
Original magnification X 100, bar 5mm.
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Figure 7 Effect of butyrate and HMBA for 48h on nucleus PBGD
fraction. (A) Western blot analysis using rabbit anti-PBGD; RCC1 is a
specific nuclear marker detected by rabbit anti RCC1. (B) The enzymatic
activity of nuclear PBGD (*Po0.05).
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Figure 8 Effect of differentiation on protein expression of ferrochelatase
in B16 melanoma cells. Cells were treated with 2.5mM butyrate or 5mM
HMBA for different times. The data shown here are from a representative
experiment repeated three times with similar results.
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s(Kriegmair et al, 1996) and basal and squamous cell carcinoma
(Betz et al, 1999), all demonstrate eminent PpIX synthesis and
specific accumulation. Our results show a direct correlation
between total PBGD (nuclear and cellular), its enzymatic activity
and PpIX accumulation. The reduced cellular PBGD following
butyrate induction resulted in a proportional decrease in the PpIX
synthesised from exogenous ALA, while HMBA treatment induced
a prominent but opposite effect of increased cellular PBGD and
PpIX production.
From the present results and from earlier studies, two patterns
of differentiation can be outlined, one associated with upregulation
and the other with downregulation of PBGD expression. Ortel et al
(1998) have shown that induction of keratinocyte differentiation
augments intracellular PpIX accumulation. Similarly, DMSO was
found to induce differentiation of B16 melanoma cells and enhance
PpIX accumulation (Schoenfeld et al, 1994) and Mamet et al (1994)
demonstrated increased activity of PBGD in malignant cell lines.
Interestingly, higher heme biosynthetic enzyme activities such as
PBGD and lower PpIX precursor concentrations were found in
Barrett’s oesophagus and adenocarcinoma of the oesophagus (Betz
et al, 1999).
Oleinick et al (2002) concluded that cell death following PDT is
in many cases due to a combination of apoptosis and necrosis.
Furthermore, even for a specific photosensitiser used for PDT, it is
difficult to determine the unique cellular response. Our results
demonstrate that ALA-PDT of B16 melanoma cells results in a
combined effect of apoptosis and necrosis, as revealed by a variety
of manifestations, including ALA-PDT-induced blebbing, DNA
laddering, membrane rupture, mitochondrial inhibition and ultra-
structural damage. The extent of cell death during ALA-PDT is
shown to be closely related to the PBGD activity and PpIX
accumulation, while the mechanism of cell death cannot be
predicted during this treatment. We may conclude that the ALA-
PDT outcome largely depends on PBGD cellular levels, which in
turn may change with specific up and down regulations during
tumour differentiation pathways.
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